BR112021011642A2 - Variantes de igg fc para uso veterinário - Google Patents

Variantes de igg fc para uso veterinário

Info

Publication number
BR112021011642A2
BR112021011642A2 BR112021011642A BR112021011642A BR112021011642A2 BR 112021011642 A2 BR112021011642 A2 BR 112021011642A2 BR 112021011642 A BR112021011642 A BR 112021011642A BR 112021011642 A BR112021011642 A BR 112021011642A BR 112021011642 A2 BR112021011642 A2 BR 112021011642A2
Authority
BR
Brazil
Prior art keywords
igg
polypeptides
various embodiments
variants
veterinary use
Prior art date
Application number
BR112021011642A
Other languages
English (en)
Inventor
Fawn Qian
Hangjun Zhan
Lam Nguyen
Richard Chin
Jiann Li Shyr
Yongzhong Li
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of BR112021011642A2 publication Critical patent/BR112021011642A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

variantes de igg fc para uso veterinário. a presente invenção refere-se a várias modalidades referentes a polipeptídeos de igg fc variante de animais de estimação apresentando ligação aumentada da proteína a para facilidade de purificação, ligação diminuída à c1q para respostas imunológicas mediadas pelo complemento reduzidas, ligação diminuída à cd16 (por exemplo, para indução reduzida de citotoxicidade celular anticorpo-dependente (adcc)), estabilidade aumentada, e/ou a capacidade de formar proteínas multiméricas. além disso, a presente invenção apresenta várias modalidades referentes a anticorpos e proteínas de fusão compreendendo tais polipeptídeos de igg fc variante. em várias modalidades, tais polipeptídeos podem ser usados para tratar animais de estimação, tais como cães, gatos e cavalos.
BR112021011642A 2018-12-27 2019-12-26 Variantes de igg fc para uso veterinário BR112021011642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785680P 2018-12-27 2018-12-27
PCT/US2019/068629 WO2020139984A1 (en) 2018-12-27 2019-12-26 Igg fc variants for veterinary use

Publications (1)

Publication Number Publication Date
BR112021011642A2 true BR112021011642A2 (pt) 2021-11-03

Family

ID=71126391

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011642A BR112021011642A2 (pt) 2018-12-27 2019-12-26 Variantes de igg fc para uso veterinário

Country Status (10)

Country Link
US (1) US20220064263A1 (pt)
EP (1) EP3902564A4 (pt)
JP (1) JP2022516027A (pt)
KR (1) KR20210110827A (pt)
CN (1) CN113453716A (pt)
AU (1) AU2019416344A1 (pt)
BR (1) BR112021011642A2 (pt)
CA (1) CA3123623A1 (pt)
MX (1) MX2021007680A (pt)
WO (1) WO2020139984A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3906259A2 (en) 2019-01-03 2021-11-10 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112021018156A2 (pt) * 2019-03-20 2021-11-16 Kindred Biosciences Inc Antagonistas de ngf para uso médico
KR20230034954A (ko) 2020-05-11 2023-03-10 인베티엑스 인코포레이티드 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
AU2022321899A1 (en) * 2021-08-06 2024-02-08 Petmedix Ltd Antibody fc variants
KR20230047014A (ko) 2021-09-29 2023-04-06 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2010117760A2 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
HUE041335T2 (hu) * 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
WO2013063186A2 (en) * 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
CN104684928A (zh) * 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA3185195A1 (en) * 2013-12-20 2015-06-25 Intervet International B.V. Antibodies against canine pd-1
CN107074952B (zh) * 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
US20200362034A1 (en) * 2017-08-15 2020-11-19 Kindred Biosciences, Inc. IgG Fc Variants for Veterinary Use
WO2020056393A1 (en) * 2018-09-14 2020-03-19 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
US20210395340A1 (en) * 2018-10-25 2021-12-23 Kindred Biosciences, Inc. IL4/IL13 Receptor Molecule for Veterinary Use
CN113423721A (zh) * 2018-12-12 2021-09-21 金德雷德生物科学股份有限公司 兽用促红细胞生成素类似物
BR112021018156A2 (pt) * 2019-03-20 2021-11-16 Kindred Biosciences Inc Antagonistas de ngf para uso médico

Also Published As

Publication number Publication date
EP3902564A4 (en) 2022-09-28
CN113453716A (zh) 2021-09-28
US20220064263A1 (en) 2022-03-03
CA3123623A1 (en) 2020-07-02
WO2020139984A1 (en) 2020-07-02
EP3902564A1 (en) 2021-11-03
MX2021007680A (es) 2021-10-13
AU2019416344A1 (en) 2021-07-01
JP2022516027A (ja) 2022-02-24
KR20210110827A (ko) 2021-09-09

Similar Documents

Publication Publication Date Title
BR112021011642A2 (pt) Variantes de igg fc para uso veterinário
MX2020001707A (es) Variantes igg fc para uso veterinario.
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
BRPI0413272A (pt) anticorpos para c-met
BRPI0414269A (pt) anticorpos para m-csf
SG11202010163QA (en) Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
JP2019511469A5 (pt)
EP3430125A4 (en) FUSION PROTEINS, RECOMBINANT BACTERIA AND EXOSPORIUM FRAGMENTS FOR USE IN ANIMAL HEALTH AND AQUACULTURE
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
DK1527100T3 (da) Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
TNSN07394A1 (en) Antibodies to myostatin
BR112018003782A2 (pt) composições e métodos para o tratamento da dor
CY1124218T1 (el) Ανασυνδυασμενοι αδενοϊικοi φορεις εμβολιων fmdv και χρησεις αυτων
EA201890856A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение у животных
IL278088A (en) Heterodimeric 3-LAG-targeted Ochi-FC proteins containing IL-15/IL-15Rα Ochi-FC proteins and 3-LAG antigen binding regions
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
MX2019012570A (es) Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.
PH12021550255A1 (en) Anti-npr1 antibodies and uses thereof
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
EA201891499A1 (ru) Химерное собачье анти-cd20 антитело
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112021020777A2 (pt) Vacina de subunidade do csfv
EA201990222A1 (ru) Антитела к o2 и пути их применения